Monday, August 3 2020


Five-in-one vaccine for babies by end of December

Update: December, 15/2015 - 18:30
Viet Nam will have 40,000 doses of five-in-one vaccine, Pentaxim, by the end of this year for the national immunisation programme. -— Photo

HA NOI (VNS) — At least 15,000 doses of Pentaxim, the five-in-one vaccine, will be available by the end of this month in the North after being in short supply for a long time.

According to report of the Centre for Biological Products and Vaccine Production Research under the Ministry of Health, this paid vaccine is undergoing quality control tests for some two weeks, and is expected to be available by the end of this month.

In the coming days, the South will also receive 25,000 doses of Pentaxim vaccine, imported from France.

The five-in-one Pentaxim vaccine is a combination of five different vaccines to protect infants against diphtheria, tetanus, whooping cough, and hepatitis B, apart from Haemophilus influenza Type B.

The ministry's Drug Administration also said that next year Viet Nam will have 49,000 doses of six-in-one vaccine, Infranrix hexa vaccine to guard against diphtheria, tetanus, whooping cough, and hepatitis B, in addition to polio and Haemophilus influenza type B.

This figure shows that next year Viet Nam will have a larger quantity of the vaccine for immunisation than the 11,000 doses it had this year.

Meanwhile, the Health Department in Dak Nong Province today announced the cause of death of a three-month old baby who received a dose of Quinvaxem, the five-in-one vaccine, in September.

According to the department's official conclusion, the baby died due to shock from the side-effects of the vaccine.

The baby was vaccinated in the local medicine centre at about 7.30am. Some 40 minutes after the vaccination, his family took him home and discovered that the baby was having difficulty breathing and his body turned purple by the afternoon. A member of his family rushed him back to the hospital but he stopped breathing in the emergency room. — VNS

Send Us Your Comments:

See also: